Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

ARNA 1.52 +0.02 (1.33%)
price chart
Here's Why Arena Pharmaceuticals, Inc. Is Struggling Today
What: Arena Pharmaceuticals (NASDAQ:ARNA) was down as much as 12% today after its marketing partner Eisai released financial results for the first half of its fiscal year.
Needham Reiterates Hold on Arena Pharmaceuticals, Inc. (ARNA) Ahead of Earnings  Smarter Analyst
Arena Pharmaceuticals Inc. (ARNA) Jumps 9.66% on February 04
Arena Pharmaceuticals Inc. (ARNA) was among the biggest gainers on the Russell 2000 for Thursday February 04 as the stock popped 9.66% to $1.59, representing a gain of $0.14 per share.
Arena Pharmaceuticals, Inc. (ARNA) Earns Hold Rating from Needham & Company LLC
Needham & Company LLC reiterated their hold rating on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in a research note issued to investors on Wednesday, MarketBeat Ratings reports.
Biotech Beach: Needham Provides Updates on Gilead Sciences, Inc. (GILD), Arena ...
The biotechnology sector is always volatile, and the recent market sell-off only makes it more so. Consequently, Alan Carr of Needham notes that it is best to focus on “commercial-stage or regulatory-stage companies with substantial cash reserves” at ...
Analyst's Roundup: Arena Pharmaceuticals, Inc.
The shares of Arena Pharmaceuticals, Inc (NASDAQ:ARNA) currently has mean rating of 2.71 while 0 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 5 recommended as “HOLD”.
How Analysts Feel About Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?  WallStreet.org
Shining on Major News: Yahoo! Inc. (NASDAQ:YHOO), Adaptimmune Therapeutics ...  Stock Transcript
Zacks Investment Research Upgrades Arena Pharmaceuticals, Inc. (ARNA) to "Buy"
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, Market Beat.
Short Interest in Arena Pharmaceuticals, Inc. (ARNA) Decreases By 22.6%  Corvus Business Newswire
EPS Forecast Of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) completed the last trading session at 1.61 after touching a high of 1.66 and a low of 1.54.
Today's Hot List: The Walt Disney Company (NYSE:DIS), Arena ...  Stock Transcript
Arena Pharmaceuticals, Inc. – Pipeline Review, Market Share, Stragegy, Size ...
MRS371 “Arena Pharmaceuticals, Inc. Global 2015 Clinical Trials Review, H2” provides an detailed overview of Arena Pharmaceuticals, Inc. scenario. Report includes top line data relating on Arena Pharmaceuticals, Inc. Global clinical trials scenario.
Arena Pharmaceuticals, Inc. (ARNA) Stock Rating Upgraded by Zacks Investment ...
Arena Pharmaceuticals logo Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, ARN reports.
Boehringer Ingelheim, Arena Pharmaceuticals to research schizophrenia drug ...  Healio
Biotech Stock under consideration today: Arena Pharmaceuticals, Inc  iStreetWire
Zacks Investment Research Lowers Arena Pharmaceuticals, Inc. (ARNA) to Hold
Zacks Investment Research cut shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) from a buy rating to a hold rating in a report released on Tuesday, AnalystRatings.